Onconetix, Inc. entered into a First Amendment to its Share Exchange Agreement with Realbotix Corp., Simulacra Corporation, and Realbotix, LLC on November 4, 2026. The amendment extends the transaction's end date to March 31, 2027, and revises the definition of Net Cash to include unpaid principal and accrued interest under a Grid Promissory Note. It also stipulates that if Net Cash is less than $12.5 million at closing, the Seller will own 95% of Onconetix's fully diluted shares. The transaction remains subject to stockholder approval and other customary closing conditions. Onconetix operates in the biotechnology sector.
